Cost-effectiveness of treatment alternatives in Parkinson's disease. An evaluation using a Markov decision analytic model

被引：0
|
作者：
Dodel, R
Spottke, A
Oertel, WH
Poewe, W
Sampaio, C
Siebert, U
机构：
来源：
MOVEMENT DISORDERS | 2002年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S4 / S4
页数：1
相关论文
共 50 条
  • [41] A cost-effectiveness clinical decision analysis model for treatment of schizophrenia
    Palmer, CS
    Brunner, E
    Ruíz-Flores, LG
    Paez-Agraz, F
    Revicki, DA
    ARCHIVES OF MEDICAL RESEARCH, 2002, 33 (06) : 572 - 580
  • [42] Cost-Effectiveness and Cost-Utility of Early Levodopa in Parkinson's Disease
    Verschuur, Constant V. M.
    Suwijn, Sven R.
    de Haan, Rob J.
    Boel, Judith A.
    Post, Bart
    Bloem, Bas R.
    van Hilten, Johannes J.
    van Laar, Teus
    Tissingh, Gerrit
    Munts, Alexander
    Dijkgraaf, Marcel G. W.
    de Bie, Rob M. A.
    JOURNAL OF PARKINSONS DISEASE, 2022, 12 (07) : 2171 - 2178
  • [43] COST-EFFECTIVENESS ANALYSIS OF INFLIXIMAB, ADALIMUMAB, AND CERTOLIZUMAB FOR CROHN'S DISEASE: A MARKOV MODEL STUDY
    Ajala, C.
    Zapata, Villa L.
    VALUE IN HEALTH, 2024, 27 (06) : S60 - S60
  • [44] COST-EFFECTIVENESS OF ELIGLUSTAT TARTRATE FOR THE TREATMENT OF TYPE 1 GAUCHER DISEASE IN CHINA USING A SEMI-MARKOV MODEL
    Xin, Y.
    He, X.
    VALUE IN HEALTH, 2024, 27 (06) : S10 - S10
  • [45] Treatment of institutionalized patients with Alzheimer's disease with quetiapine: A cost-effectiveness evaluation
    Getsios, D
    O'Brien, J
    Caro, JJ
    Pesa, J
    VALUE IN HEALTH, 2005, 8 (03) : 254 - 254
  • [46] EVALUATION OF DECISION ANALYTIC MODELS IN COST-EFFECTIVENESS ANALYSIS IN KOREA: FROM GUIDELINE TO PRACTICE
    Bae, S.
    Lee, S.
    Lim, S. H.
    VALUE IN HEALTH, 2012, 15 (04) : A164 - A164
  • [47] Decision-analytic evaluation of the clinical effectiveness and cost-effectiveness of management programmes in chronic heart failure
    Goehler, Alexander
    Conrads-Frank, Annette
    Worrell, Stewart S.
    Geisler, Benjamin P.
    Halpern, Elkan F.
    Dietz, Rainer
    Anker, Stefan D.
    Gazelle, G. Scott
    Siebert, Uwe
    EUROPEAN JOURNAL OF HEART FAILURE, 2008, 10 (10) : 1026 - 1032
  • [48] Impact on the Incremental Cost-Effectiveness Ratio of Using Alternatives to EQ-5D in a Markov Model for Multiple Sclerosis
    Versteegh, Matthijs
    PHARMACOECONOMICS, 2016, 34 (11) : 1133 - 1144
  • [49] Impact on the Incremental Cost-Effectiveness Ratio of Using Alternatives to EQ-5D in a Markov Model for Multiple Sclerosis
    Matthijs Versteegh
    PharmacoEconomics, 2016, 34 : 1133 - 1144
  • [50] COST-EFFECTIVENESS ANALYSIS OF A HYPOTHETICAL DISEASE MODIFYING THERAPY FOR PARKINSON'S DISEASE
    Chandler, C.
    Gal, P.
    Folse, H.
    Chavan, A.
    Ward, A.
    VALUE IN HEALTH, 2020, 23 : S633 - S633
12345